Breaking News: Pressure BioSciences' PCT Platform Highlighted at International Conference in China | Financial Buzz

Breaking News: Pressure BioSciences’ PCT Platform Highlighted at International Conference in China

Scientists from the Elite Westlake University Report on the Use of the PCT Platform to Significantly Improve the Preparation of Clinical Laboratory Specimens for Evaluation

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guos Westlake laboratory was named a PBI Center of Excellence.

Professor Guo and internationally recognized proteomics expert Professor Ruedi Aebersold (ETH-Zurich, Switzerland) are the co-developers of PCT-SWATH, a breakthrough method in high throughput proteomic sample analysis. PCT-SWATH is a novel proteomics method that combines the unique capabilities of PBIs patented pressure cycling technology (PCT) for sample preparation (a critical step in the research process) with the cutting-edge analytical capabilities of SCIEXs mass spectrometry SWATH method. Data strongly indicate that PCT-SWATH allows scientists to reproducibly identify, extract, and quantify more proteins from complex samples types in a shorter time period than other current methods, potentially facilitating the path to earlier and superior biological insights and discoveries.

Under Professor Guos leadership and direction, his laboratory at Westlake University has grown to have the largest number of PCT Barocycler systems in the world, with eight instruments to meet the demand of preparing thousands of tissue samples for analysis. Professor Guo said: Many of the studies on cancer biopsy tissues performed at Westlake and in the laboratories of our collaboration partners rely critically on PBIs PCT platform to rapidly and reproducibly extract high quality proteins from tumor tissues for analysis by mass spectrometry. It is hoped that such activities will eventually result in the discovery of new biomarkers of disease and possibly even new drug targets.

Professor Guo continued: PCT is a novel, enabling technology platform. My team and I believe that the PCT platform can help researchers worldwide make new discoveries in multiple fields, including proteomics, genomics, and metabolomics. We were able to use used the Westlake University conference to educate research scientists on the features and benefits of the PCT platform. Many scientists left the conference with an excellent understanding of the advantages of PCT, and how this platform technology can help them in their research, especially in the area of preparing cancer biopsy samples for evaluation. We believe the use of the PCT platform will continue to grow in China and elsewhere.

Roxana McCloskey, Global Director of Sales and Marketing for PBI, said, We are very pleased that the PCT platform was featured in several presentations during the three-day Westlake Conference and was the focus of a scientific session entitled Reproducible preparation of clinical specimens using Pressure Cycling Technology. On the third day of the conference, many attendees participated in a hands-on workshop that demonstrated the use of the PCT platform in preparing high quality tissue biopsy samples for evaluation, a very large market opportunity for PBI (the aspiration and biopsy needle market alone is projected to reach $1.27 billion by 2024. Research and Markets, July 2019).

Ms. McCloskey continued: Our Chinese distributor (PowerTech Technology Co.) attended the conference and had the opportunity to speak with many potential customers about the Barocycler 2320EXTREME. We believe this conference has significantly increased awareness of our PCT platform among protein scientists in China and other countries, and that it will result in a number of instrument sales in the future.

About Westlake University

Westlake University is a non-profit research institute dedicated to the advancement of natural sciences and the frontiers of engineering disciplines. Located in the beautiful Cloud Town of Xihu District, Hangzhou, China, Westlake University strives to represent the scientific strength of China, to influence the nations future, and to promote inclusive development and progress. Westlake University aims at establishing a top-level research-oriented global university. At Westlake University, scientific knowledge and technological advancement are utilized to have a real-life impact on the world and to benefit human beings. Leading talent with innovative spirit and capabilities are trained to become the driving force of Chinas development.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (UST) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a one-year agreement with pressure biosciences inc. for fifty thousand restricted common shares for continued financial and corporate news dissemination. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: